Skip to main content
logo
Alphamab Oncology (HKG:9966)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.58
+0.02 (0.26%)
Jul 30, 2026, 4:08 PM HKT

Alphamab Oncology Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
566.24566.24640.08218.77166.85146.02
Revenue Growth
-27.96%-11.54%192.58%31.12%14.26%-
Gross Profit
502.69502.69579.77163.54122.64142.99
Operating Income
-153.29-153.29101.01-323.33-432.37-415.62
Net Income
-113.94-113.94166.34-210.59-325.72-412.42
Earnings Per Share
-0.12-0.120.17-0.22-0.35-0.44
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,3501,3501,5711,4071,3501,985
Total Debt
122.98122.98185.96257.08345.39637.27
Net Cash (Debt)
1,2271,2271,3861,1501,0051,348
Net Cash Growth
-10.50%-11.42%20.46%14.45%-25.46%-26.78%
Net Cash Per Share
1.281.281.411.201.071.44

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-121.89-121.89212.34-202.84-300.31-320.6
Capital Expenditures
-31.59-31.59-21.77-36.18-129.65-158.12
Free Cash Flow
-153.48-153.48190.56-239.02-429.96-478.72
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
88.78%88.78%90.58%74.75%73.50%97.93%
Operating Margin
-27.07%-27.07%15.78%-147.79%-259.14%-284.63%
Pretax Margin
-20.12%-20.12%25.99%-96.26%-195.22%-282.44%
Profit Margin
-20.12%-20.12%25.99%-96.26%-195.22%-282.44%
FCF Margin
-27.11%-27.11%29.77%-109.26%-257.70%-327.84%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--19.03---
P/FCF Ratio
--16.61---
PS Ratio
11.6215.064.9526.5853.8171.10